Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanomaJulia A Newton-Bishop, Samantha Beswick, Juliette Randerson-Moor, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2009
Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR dataJuliette A Randerson-Moor, John C Taylor, Faye Elliott, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 25, 2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-upJohn C Mathers, Faye Elliott, Finlay Macrae, et al.
Plos One|February 10, 2018
Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populationsHarsh Sheth, Emma Northwood, Cornelia M Ulrich, et al.
Lancet (London, England)|June 15, 2020
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trialJohn Burn, Harsh Sheth, Faye Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2021
Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal CancerChristopher J M Williams, Jenny F Seligmann, Faye Elliott, et al.
The New England Journal of Medicine|December 17, 2008
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndromeJohn Burn, D Timothy Bishop, Jukka-Pekka Mecklin, et al.
The Lancet. Oncology|November 13, 2012
Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialJohn C Mathers, Mohammad Movahedi, Finlay Macrae, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2026
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trialJohn Burn, Gillian M Borthwick, Faye Elliott, et al.
Lancet (London, England)|November 1, 2011
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialJohn Burn, Anne-Marie Gerdes, Finlay Macrae, et al.
Pageof 5